drugset / Trial / NCT07238686
Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety and efficacy of a Venetoclax and hypomethylating agent-based regimen combined with infusion of HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cells (GPBMC) in patients with intermediate-risk and higher myelodysplastic syndromes who are ineligible for allogeneic hematopoietic stem cell transplantation.
Timeline
- Start
- 2025-06-20
- Primary completion
- 2030-06
- Completion
- 2031-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |